XM non fornisce servizi ai residenti degli Stati Uniti d'America.

Growth-hungry EQT boss faces an M&A puzzle



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BREAKINGVIEWS-Growth-hungry EQT boss faces an M&A puzzle</title></head><body>

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

By Liam Proud

LONDON, Oct 17 (Reuters Breakingviews) -Christian Sinding is making no secret of the fact that his $40 billion private-markets group EQT EQTAB.ST wants to buy one of its peers. But he has two problems: high prices, and an acquisition currency that may be a turnoff.

The Stockholm-based buyouts-to-property group frequently mentions M&A, but its focus seems to be intensifying. Sinding said in a third-quarter message to investors that EQT was looking to strengthen its business “organically or through acquisitions”.

The private-market sector is consolidating. Earlier this year, BlackRock spent $12.5 billion on Global Infrastructure Partners, while General Atlantic bought fund manager Actis, which had $12.5 billion of assets at the time. CVC Capital Partners also went public, giving it an acquisition currency. The general sense among executives and advisers is that fundraising will be tougher in the future, and that the biggest and most diversified managers will have the most staying power.

Sinding has mentioned so-called secondaries businesses as a target. Traditionally, these vehicles buy stakes in other private equity funds. Probably the biggest deal would be France’s privately-held Ardian, with $166 billion of assets as of the first quarter of 2024. But Sinding might prefer to home in on a more focused target that specialises in so-called general partner-led secondaries, which involves buying minority stakes in companies owned by other private equity groups, typically through special vehicles known as continuation funds.

Total transactions in this business, known as GP-led secondaries, will hit $65 billion this year, investment bank Jefferies reckons, which is close to the 2021 peak. This business is thriving as buyout managers try to find alternative solutions for companies they are struggling to sell or list. Because these deals tend to include stakes in mature companies, they are also more liquid and therefore easier to sell to wealthy retail investors, another growth area for EQT. Major players include $8 billion Intermediate Capital Group and employee-owned HarbourVest, which might be too large and complicated to swallow, or Pantheon – part of New York-listed $6 billion Affiliated Managers.

Sellers know that buyers are eager to bulk up, making it easy to demand a high price. Tiny U.S. secondaries specialist Kline Hill is currently on the block for $500 million, Bloomberg reported, implying an eyebrow-raising 12% of assets under management. That’s roughly double the ratio that Ares Management paid for Landmark Partners, another secondaries firm, in 2021, according to Breakingviews calculations.

The other problem is that EQT’s Sweden-listed stock, with a fairly low free float of around 40%, isn’t the most liquid acquisition currency. That won’t be a problem if Sinding decides to pay in cash, but that limits him to relatively small acquisitions. In other words, EQT’s M&A quest is fraught with problems.

Follow @Breakingviews on X


CONTEXT NEWS

EQT on Oct. 17 said that it was assessing “strategic opportunities, organically or through acquisitions” to boost its business. In the past, it has bought rival private-capital managers like Baring Private Equity Asia in 2022 and real-estate specialist Exeter Property in 2021.


Rising multiples for private-market firms https://reut.rs/3zZYnNW


Editing by George Hay and Streisand Neto

</body></html>

Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.

Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.

Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.

Avvertenza sul rischio: Il tuo capitale è a rischio. I prodotti con leva finanziaria possono non essere adatti a tutti. Ti chiediamo di consultare attentamente la nostra Informativa sul rischio.